Anker Espen, Haavik Jan, Heir Trond
Oslo ADHD clinic, Oslo 0366, Norway.
Department of Biomedicine, University of Bergen, Bergen 5007, Norway.
World J Psychiatry. 2020 Sep 19;10(9):202-211. doi: 10.5498/wjp.v10.i9.202.
High risk of alcohol and drug use disorders in people with attention-deficit/hyperactivity disorder (ADHD) calls for exploratory research of relationships with clinical features of ADHD.
To estimate prevalence of alcohol/drug use disorders and associations with ADHD symptom severity and emotional dysregulation, in adults with ADHD.
This observational cross-sectional clinical study consisted of patients admitted to a private psychiatric outpatient clinic in Oslo, Norway (2014-2018). Five-hundred and fifty-eight eligible patients diagnosed with ADHD (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria) agreed to participate. Alcohol and drug use disorders were diagnosed using the Mini International Neuropsychiatric Interview (MINI). Dependence and abuse were merged into "use" disorder as in MINI version 7.0/DSM-5. Questions were related both to lifetime and the past 12-mo. ADHD severity was assessed by the Adult ADHD Self Report Scale (ASRS). Subdivisions of the ASRS questionnaire as inattentive items and hyperactive/impulsivity items were recorded separately. Emotional dysregulation was assessed by the eight-item version of Barkley's Current Behavior Scale - Self Report.
The 12-mo prevalence was 5.3% for alcohol use disorder and 13.7% for drug use disorder. The lifetime prevalence was 12.0% for alcohol use disorder and 27.7% for drug use disorder. Men had higher rates of both alcohol use disorder and drug use disorder compared to women. The prevalence of drug use disorder was more than twice that of alcohol use disorder for both sexes. The drugs most participants reported having used were (in descending order): Amphetamine (19.1%), cannabis (17.1%), cocaine or ecstasy (7.4%), benzodiazepines (7.4%), and heroin or other opioids (2.9%). Lifetime drug use disorder was significantly associated with both hyperactivity-impulsivity symptoms and emotional dysregulation symptom severity. Lifetime alcohol use disorder, on the other hand, was not significantly associated with ADHD symptoms or emotional dysregulation when adjusted for gender and age.
Patients with ADHD have a high lifetime prevalence of drug use disorder, which is associated with higher levels of hyperactivity-impulsivity symptoms and emotional dysregulation.
注意力缺陷多动障碍(ADHD)患者存在酒精和药物使用障碍的高风险,这需要对其与ADHD临床特征的关系进行探索性研究。
评估ADHD成人患者中酒精/药物使用障碍的患病率及其与ADHD症状严重程度和情绪失调的关联。
这项观察性横断面临床研究纳入了挪威奥斯陆一家私立精神科门诊诊所收治的患者(2014 - 2018年)。558名符合条件且被诊断为ADHD(依据《精神疾病诊断与统计手册》第五版(DSM - 5)标准)的患者同意参与研究。使用迷你国际神经精神访谈(MINI)诊断酒精和药物使用障碍。按照MINI 7.0/DSM - 5的标准,将依赖和滥用合并为“使用”障碍。问题涉及终生情况以及过去12个月的情况。通过成人ADHD自我报告量表(ASRS)评估ADHD严重程度。ASRS问卷中的注意力不集中项目和多动/冲动项目分别记录。通过巴克利当前行为量表 - 自我报告的八项版本评估情绪失调。
酒精使用障碍的12个月患病率为5.3%,药物使用障碍的患病率为13.7%。酒精使用障碍的终生患病率为12.0%,药物使用障碍的终生患病率为27.7%。男性的酒精使用障碍和药物使用障碍发生率均高于女性。男女的药物使用障碍患病率均是酒精使用障碍患病率的两倍多。大多数参与者报告使用过的药物依次为:苯丙胺(19.1%)、大麻(17.1%)、可卡因或摇头丸(7.4%)、苯二氮䓬类药物(7.4%)以及海洛因或其他阿片类药物(2.9%)。终生药物使用障碍与多动 - 冲动症状和情绪失调症状严重程度均显著相关。另一方面,在对性别和年龄进行调整后,终生酒精使用障碍与ADHD症状或情绪失调无显著关联。
ADHD患者终生药物使用障碍患病率较高,这与较高水平的多动 - 冲动症状和情绪失调相关。